Welcome to our dedicated page for Vericel SEC filings (Ticker: VCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vericel Corporation (VCEL) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed issuer, Vericel files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits and financial statements.
Through these documents, investors can review detailed financial information about Vericel’s business in advanced therapies for sports medicine and severe burn care. The filings describe revenue by product category, including MACI and Burn Care (Epicel and NexoBrid), gross margin, operating expenses, net income or loss, cash and investments, and non-GAAP measures such as adjusted EBITDA. Management explains its use of non-GAAP metrics and provides reconciliations to GAAP results.
Vericel’s Form 8-K filings often furnish press releases announcing quarterly financial results, such as the reports for the quarters ended June 30 and September 30, 2025. These current reports give timely insight into performance trends, business highlights, manufacturing scale-up activities and clinical program updates, including MACI Ankle studies and facility qualification efforts.
Annual and quarterly reports also contain risk factor and forward-looking statement sections that outline uncertainties related to revenue growth, market penetration for MACI, MACI Arthro, Epicel and NexoBrid, manufacturing capacity, reimbursement dynamics, surgeon and burn center adoption, supply chain issues and broader macroeconomic and geopolitical conditions.
On Stock Titan, Vericel’s filings are supplemented with AI-powered summaries that highlight key points from lengthy 10-K and 10-Q documents, explain complex accounting or non-GAAP metrics in plain language, and surface notable items from Form 4 insider transaction reports when available. Real-time updates from EDGAR help users track new VCEL filings as they are posted, while AI-generated overviews make it easier to understand how each filing relates to Vericel’s business in cell therapies and specialty biologics.
Vericel Corp Chief Medical Officer Jonathan Mark Hopper exercised and sold a small block of shares in a pre-planned transaction. On April 2, 2026 he exercised stock options for 3,472 shares of common stock at $10.95 per share and sold the same 3,472 shares at $35.00 per share under an automatic Rule 10b5-1 trading plan. After these transactions, he directly holds 75,556 Vericel common shares and 9,132 stock options that are exercisable at $10.95 per share and expire on August 20, 2028.
Vericel Corp reports that Soleus Capital Master Fund, L.P. and affiliated entities hold 2,549,079 shares of common stock. The filing states this equals 5.0% of Vericel's outstanding common shares, based on 50,763,319 shares outstanding as of February 19, 2026. The ownership is reported as shared voting and dispositive power among the fund and affiliated entities, with Guy Levy identified as the managing member signing the joint filing agreement.
Vericel Corp director Alan L. Rubino exercised stock options to acquire 15,000 shares of common stock at $2.76 per share and chose to hold all of these shares. These options were originally granted on May 4, 2016 and would otherwise have expired on May 4, 2026. Following the exercise, Rubino directly owns 60,994 shares of Vericel common stock, and the exercised option grant has been fully used with no remaining derivative position from this award.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting zero beneficial ownership of Vericel Corp common stock. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report ownership separately and Vanguard no longer is deemed to beneficially own those securities.
The filing lists Amount beneficially owned: 0 and Percent of class: 0%, and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Vericel director Heidi Hagen exercised stock options to acquire 15,000 shares of common stock at an exercise price of $2.76 per share, then sold the same 15,000 shares at $32.41 per share on March 23, 2026.
The sale was carried out automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 14, 2024. These options were originally granted on May 4, 2016 and would have expired on May 4, 2026 if not exercised. Following the transactions, Hagen holds 31,850 shares of Vericel common stock directly.
Vericel Corporation reports a strong 2025 and asks shareholders to vote on key governance items at its virtual annual meeting on April 29, 2026. Total net revenue reached $276.3 million, with MACI contributing $239.5 million, up 21% and marking a third straight year of 20%+ growth.
Gross margin improved to 74%, non-GAAP adjusted EBITDA was $70.9 million (up 33%), and GAAP net income was $16.5 million, a 59% increase and the second consecutive profitable year. The company ended 2025 with nearly $200 million in cash and investments and no debt.
Growth was driven by MACI and the arthroscopic MACI Arthro technique, expansion of the sales force, and a burn care franchise that generated $36.8 million in revenue. Vericel initiated the MACI Ankle MASCOT phase 3 study and secured FDA approval for commercial MACI manufacturing at its new advanced facility, supporting a planned MACI launch in the United Kingdom in 2027.
Shareholders are being asked to elect seven directors, approve on an advisory basis executive compensation, and ratify the appointment of PricewaterhouseCoopers LLP as independent auditor for 2026. The proxy also highlights robust governance practices, director pay structure, and stock ownership guidelines.
Vericel Corp’s Chief Legal Officer Sean C. Flynn exercised options for 15,000 shares and sold a total of 21,421 common shares of VCEL on March 2, 2026. The sales, executed at prices around $34.75 and $35.36, were made under an automatic Rule 10b5-1 trading plan adopted on December 2, 2025. Following these transactions, Flynn directly held 1,262 common shares and 85,000 option-based rights.